Niramas Utama Tbk. vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Niramas Utama Tbk. trades at Rp1,005 (market cap 1.31T, 64.48M 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp248 (market cap 167.37B, 96.7K 24h volume). The key difference: Niramas Utama Tbk. is far larger — about 7.8× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Niramas Utama Tbk. is more actively traded (64.48M versus 96.7K). Which is the better fit depends on your goals.
| JELI | OBAT | |
|---|---|---|
Market Cap | 1.31T | 167.37B |
Volume | 64.48M | 96.7K |
Lot | 644.81K | 967 |
Turnover | 65.83B | 23.82M |
Average Price | 1,020.91 | 246.34 |
Value | 65.83B | 23.82M |
Indicative Equilibrium Price | 1,005 | 248 |
Indicative Equilibrium Volume | 24.22K | 41 |
Trailing returns across standard periods
Latest headlines on both assets
PT. Niramas Utama Tbk. (the Company) formerly PT Nata Sari Raya was established based on Notarial Deed No. 86 dated 22 November 1990, by Notary Samsul Hadi, S.H. The Company started its commercial operations in 1994. The parent entity and the ultimate parent entity of the Company are PT Niramas Utama International and PT Supra Sentral Investama
Read more on JELI →PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →